{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RLMD",
  "name": "Relmada Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/RLMD/",
  "json_url": "https://frontierpicks.com/dossiers/RLMD.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The level this coverage was framed around broke: the 2026-08-21 weekly close of $4.63 is under the $4.75 March PIPE strike, and it broke on no disclosure. With the 2026 clinical calendar emptied on the 2026-08-06 call, what remains is a pre-IND asset with $217.7M of cash and a first Phase 3 readout guided to 1H 2027.",
  "invalidation_trigger": "A weekly close below $4.25 — roughly 10% under the March PIPE issue price, whose $4.75 shelf already failed on the 2026-08-21 weekly close at $4.63. Secondary: no NDV-01 IND submission announced by 2026-12-31, which pushes first Phase 3 data past the guided 1H 2027.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage, no revenue. As of 2026-08-06 NDV-01 remains pre-IND; every valuation input is company guidance, not filed regulatory progress.",
    "That price set the institutional book.",
    "An effective S-3 shelf remains on file. Runway guided through 2029 removes financing urgency but not the ability to issue.",
    "The 2022-10-13 RELIANCE II failure of REL-1017 is the credibility event this management team still trades against.",
    "NMIBC competitive set to track: J&J TAR-200, CG Oncology cretostimogene, ImmunityBio Anktiva (approved). NDV-01 competes on delivery over a gem/doce backbone.",
    "Added to Russell 2000/3000 effective 2026-06-26; a share of daily volume is index-mechanical rather than fundamental."
  ],
  "body_markdown": "## Current Thesis\n\nThe level this coverage had built the frame around went on 2026-08-21. The adjusted daily series closed the week at $4.63, beneath the $4.75 at which the March 2026 PIPE was struck — The condition published on 2026-08-15, a weekly close below $4.75, has therefore fired, and it fired quietly: no company release or fresh guidance surfaced in public news aggregation between the 2026-08-06 Q2 update and the 2026-08-21 close.\n\nThe narrative leg on offer is no longer the oncology-pivot re-rate that carried the name from the 2026-03-09 Phase 2 interim into the June Russell add. It is cash-covered optionality on a 2027 binary: an asset still pre-IND as of 2026-08-06, an FDA-agreed registrational design, $217.7M of cash and investments at 2026-06-30, and a first Phase 3 disclosure guided to 1H 2027 after 15–20 patients are evaluated. Between now and the year-end IND deadline there is no dated clinical event the company does not itself control.\n\n## Bull Case\n\n- The 2026-03-09 12-month Phase 2 interim: 95% complete response at any time, 76% CR at 12 months in high-risk NMIBC, 80% CR at 12 months in the BCG-unresponsive cohort, no progression to muscle-invasive disease, no radical cystectomies, no grade 3+ treatment-related adverse events. The alternative in BCG-unresponsive disease is bladder removal.\n- The 2026-08-06 release states design and primary endpoints for both registrational pathways were confirmed via *written* FDA feedback. The RESCUE primary endpoint is complete response rate at any time, crediting reinduction after three months rather than a fixed three-month assessment.\n- Operational readiness runs ahead of the regulatory clock: roughly 80 sites engaged (60 primary, 20 backup), and on the 2026-08-06 call management said enrollment can technically begin 30 days after IND filing.\n- $217.7M cash and investments at 2026-06-30 against Q2 operating cash use of $9.6M, guided through 2029 including completion of RESCUE. Q2 loss was $(0.11) per share versus a $(0.20) consensus estimate — the pre-Phase-3 burn is running under where the street modelled it.\n- The sell-side did not follow the tape down after the guidance reset. Piper Sandler reiterated Buy with a $12 target on 2026-08-07, H.C. Wainwright Buy $12 on 2026-08-10, Mizuho Buy $19 on 2026-08-11. The S&P Global-polled consensus as of 2026-08-23 is Strong Buy, average $12.67 across six analysts, range $9.00–$19.00.\n- Sepranolone remains an unpriced second asset, with IND guided by year-end 2026 and a Phase 2 proof-of-concept in Prader-Willi syndrome on clearance.\n\n## Bear Case\n\n- The only dated clinical event left in 2026 is a regulatory filing the company controls. On 2026-08-06 the previously promised end-2026 three-month interim was replaced with 1H 2027 first Phase 3 data; in March the program had been guided to *initiate* mid-2026.\n- The reason given for the slip was contract-manufacturing scheduling — an external dependency with no fix the company can announce. The same constraint gates the sepranolone pre-filled syringe, so both year-end 2026 INDs sit behind one bottleneck.\n- The March book is now underwater. The $4.75 strike that had acted as a floor through the summer became a failed level on the 2026-08-21 weekly close, and the index-mechanical demand from the Russell 2000/3000 add effective 2026-06-26 is spent.\n- An effective S-3 shelf remains on file. Runway guidance through 2029 removes the need to raise; it does not remove the option to.\n- A $12.67 average target against a $4.63 close is a 2.7x gap on an unstarted trial. Pre-IND NPV models are not a floor and can be cut on timeline alone.\n- The 2022-10-13 RELIANCE II failure of REL-1017 is the reason this management team gets no benefit of the doubt on a guidance reset.\n\n## Setup & Price Structure\n\nThe 2026-08-21 close of $4.63 sits 41.1% below the $7.86 52-week high; the shares are down 34.2% over three months, and RSI(14) reads 31.7 against 39.4 on 2026-08-14. That is a grind lower rather than a capitulation flush — a two-week continuation on no disclosure after the catalyst deletion, not a single gap.\n\nThe narrative is **dead**, applied to the narrative leg rather than to the company. The dating is specific — the re-rate ran from the 2026-03-09 interim through the 2026-06-26 index add, the forcing function was removed on 2026-08-06, and the price structure that held it broke on 2026-08-21 when the PIPE strike gave way. The $4.75 area now sits overhead. Below it the public record offers no post-March reference price, which is why the next gradeable break is set at a weekly close below $4.25.\n\nPositioning and crowding observables, stated as observables: price is below rather than above a rising average, with RSI(14) at 31.7; three Buy targets were refreshed on 2026-08-07, 08-10 and 08-11 into a tape that fell over the following two weeks; the Russell-driven share of daily flow post-2026-06-26 is mechanical; an effective S-3 sits behind a stock trading under its last issue price; and there is no earnings date inside the next 30 days to force a repricing either way.\n\n## Catalyst Calendar (next 30 days)\n\n- **None company-confirmed between 2026-08-23 and 2026-09-22.** No scheduled readout, filing deadline or investor event is on the public calendar in this window.\n- ~2026-11-05 (est.) — Q3 2026 results and business update. First checkpoint on whether \"by year-end 2026\" for the NDV-01 IND survives, and the first read on burn as sites activate.\n- 2026-12-31 — guided NDV-01 IND submission deadline. RESCUE cannot enroll before clearance.\n- 2026-12-31 — guided sepranolone IND submission.\n- ~2027-06-30 (est., 1H 2027 guided) — first Phase 3 RESCUE data after 15–20 patients evaluated.\n\n## What Would Change Our Mind\n\nThe structure that broke is reclaimable, and the reclaim is the cleanest constructive datapoint available before November: weekly closes back above $4.75 would put the March book whole again and re-establish the level the summer range was built on. An IND submission announced meaningfully ahead of 2026-12-31 would do more, because it converts the one 2026 event from a deadline into an evidence point and starts the 30-day clock to enrollment management described on 2026-08-06.\n\nContinuation the other way is defined at a weekly close below $4.25, roughly 10% under the PIPE issue price and the point at which the post-March range has no remaining reference. Two non-price conditions would independently break what is left of the case: an IND submission not announced by 2026-12-31, which by management's own sequencing pushes first data past the guided 1H 2027; or a registered offering priced off the shelf, which would contradict the 2029 runway framing while the stock trades under $4.75. On the fundamental side, quarterly operating cash use stepping materially above the $9.6M Q2 rate before enrollment begins would make the runway guidance a moving number.\n\n## Correlation Notes\n\n- No revenue, so the name carries no macro or customer correlation. What it does track is small-cap biotech risk appetite and the sector financing window — XBI-type beta, amplified by a sub-$500M market profile and a live shelf.\n- Index-mechanical: added to the Russell 2000/3000 effective 2026-06-26, so a portion of daily volume follows index flows independent of the story.\n- Read-across risk in NMIBC is one-directional here. Durable-CR datasets or approvals from J&J's TAR-200 or CG Oncology's cretostimogene set the bar NDV-01's 2027 data must clear, and ImmunityBio's Anktiva is already approved in the indication.\n- Rate path matters through the discount rate on a 2027-plus cash-flow story with the entire value in terminal assumptions.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-23T16:35:05+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}